Monte Rosa Therapeutics (GLUE) Stock Statistics & Valuation Metrics

Monte Rosa Therapeutics has a market cap or net worth of $903.21M. The enterprise value is $754.33M.

Market Cap

$903.21M

Enterprise Value

$754.33M

Monte Rosa Therapeutics has 85,450,120 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

85,450,120

Owned by Insiders

8.86%

Owned by Institutions

34.03%

Monte Rosa Therapeutics’s return on equity (ROE) is -0.17 and return on invested capital (ROIC) is -13.56%.

Return on Equity (ROE)

-0.17

Return on Assets (ROA)

-0.09

Return on Invested Capital (ROIC)

-13.56%

Return on Capital Employed (ROCE)

-0.14

Revenue Per Employee

714.87K

Profits Per Employee

-223.27K

Employee Count

173

Asset Turnover

0.28

Inventory Turnover

0.00

The current PE Ratio of Monte Rosa Therapeutics is -6.19. Monte Rosa Therapeutics’s PEG ratio is -0.05.

PE Ratio

-6.19

PS Ratio

12.83

PB Ratio

2.17

Price to FCF

-5.18

Price to Operating Cash Flow

-6.51

PEG Ratio

-0.05

In the last 12 months, Monte Rosa Therapeutics had revenue of 123.67M and earned -38.63M in profits. Earnings per share was -0.59.

Revenue

123.67M

Gross Profit

115.32M

Operating Income

-54.21M

Pretax Income

-39.72M

Net Income

-38.63M

EBITDA

-31.37M

Earnings Per Share (EPS)

-0.59

In the last 12 months, operating cash flow was -165.47M and capital expenditures -8.92M, giving a free cash flow of -174.39M billion.

Operating Cash Flow

-165.47M

Free Cash Flow

-174.39M

Free Cash Flow per Share

-1.71

Monte Rosa Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-19.41%

Earnings Yield

-12.22%

Beta

1.69

52-Week Price Change

-18.75%

50-Day Moving Average

11.71

200-Day Moving Average

16.96

Relative Strength Index (RSI)

44.99

Average Volume (3m)

1.29M

Monte Rosa Therapeutics upcoming earnings date is Mar 18, 2027, TBA (Not Confirmed).

Last Earnings Date

Nov 05, 2026

Next Earnings Date

Mar 18, 2027

Ex-Dividend Date

―

Monte Rosa Therapeutics as a current ratio of 6.12, with Debt / Equity ratio of 16.82%

Current Ratio

6.12

Quick Ratio

6.12

Debt to Market Cap

0.03

Net Debt to EBITDA

2.89

Interest Coverage Ratio

0.00

In the past 12 months, Monte Rosa Therapeutics has paid -1.10M in taxes.

Income Tax

-1.10M

Effective Tax Rate

0.03

Monte Rosa Therapeutics EV to EBITDA ratio is -7.30, with an EV/FCF ratio of -5.10.

EV to Sales

12.65

EV to EBITDA

-7.30

EV to Free Cash Flow

-5.10

EV to Operating Cash Flow

-5.38

Monte Rosa Therapeutics has $577.73M in cash and marketable securities with $36.27M in debt, giving a net cash position of $541.46M billion.

Cash & Marketable Securities

$577.73M

Total Debt

$36.27M

Net Cash

$541.46M

Net Cash Per Share

$6.34

Tangible Book Value Per Share

$4.87

Gross margin is 97.11%, with operating margin of -214.46%, and net profit margin of -186.24%.

Gross Margin

97.11%

Operating Margin

-214.46%

Pretax Margin

-184.77%

Net Profit Margin

-186.24%

EBITDA Margin

-173.14%

EBIT Margin

-184.77%

The average price target for Monte Rosa Therapeutics is $25.14, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

$25.14

Price Target Upside

137.87% Upside

Analyst Consensus

Strong Buy

Analyst Count

8

Revenue Growth Forecast

-61.26%

EPS Growth Forecast

-597.59%

Smart Score

9

AI Score

54